Decreased serum adrenal androgen dehydroepiandrosterone sulfate and mortality in hemodialysis patients

Nephrology Dialysis Transplantation

Volumn 27, Issue 10, 2012, Pages 3915-3922

  Kakiya, Ryusuke ^a,b   Shoji, Tetsuo ^a   Hayashi, Tomoshige ^a   Tatsumi Shimomura, Naoko ^b   Tsujimoto, Yoshihiro ^b   Tabata, Tsutomu ^b   Shima, Hideaki ^a   Mori, Katsuhito ^a   Fukumoto, Shinya ^a   Tahara, Hideki ^a   Koyama, Hidenori ^c   Emoto, Masanori ^a   Ishimura, Eiji ^a   Nishizawa, Yoshiki ^a   Inaba, Masaaki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Inoue Hospital   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

cardiovascular disease; dehydroepiandrosterone sulfate; hemodialysis; mortality; risk factor

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; PRASTERONE SULFATE;

ADULT; AGE; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEMODIALYSIS PATIENT; HORMONE BLOOD LEVEL; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; SURVIVAL; URBAN AREA;

ADULT; AGED; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; COHORT STUDIES; DEHYDROEPIANDROSTERONE SULFATE; FEMALE; HUMANS; JAPAN; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN-ENERGY MALNUTRITION; RENAL DIALYSIS;

EID: 84868601083     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs162     Document Type: Article

References (40)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112-S119
2. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-2169
3. Fouque D, Kalantar-Zadeh K, Kopple J et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 2008; 73: 391-398
4. Nishizawa Y, Shoji T, Ishimura E. Body composition and cardiovascular risk in hemodialysis patients. J Ren Nutr 2006; 16: 241-244
5. Kakiya R, Shoji T, Tsujimoto Yet al. Body fat mass and lean mass as predictors of survival in hemodialysis patients. Kidney Int 2006; 70: 549-556
6. Dong J, Ikizler TA. New insights into the role of anabolic interventions in dialysis patients with protein energy wasting. Curr Opin Nephrol Hypertens 2009; 18: 469-475
7. Kalantar-Zadeh K, Abbott KC, Kronenberg F et al. Epidemiology of dialysis patients and heart failure patients. Semin Nephrol 2006; 26: 118-133
8. Oreopoulos A, Padwal R, Kalantar-Zadeh K et al. Body mass index and mortality in heart failure: a meta-analysis. Am Heart J 2008; 156: 13-22
9. Jankowska EA, Biel B, Majda J et al. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation 2006; 114: 1829-1837
10. Barrett-Connor E, Khaw KT et al. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med 1986; 315: 1519-1524
11. Trivedi DP, Khaw KT. Dehydroepiandrosterone sulfate and mortality in elderly men and women. J Clin Endocrinol Metab 2001; 86: 4171-4177
12. Kahonen MH, Tilvis RS, Jolkkonen J et al. Predictors and clinical significance of declining plasma dehydroepiandrosterone sulfate in old age. Aging (Milano) 2000; 12: 308-314
13. Tilvis RS, Kahonen M, Harkonen M. Dehydroepiandrosterone sulfate, diseases and mortality in a general aged population. Aging (Milano) 1999; 11: 30-34
14. Feldman HA, Johannes CB, Araujo AB et al. Low dehydroepiandrosterone and ischemic heart disease in middle-aged men: prospective results from the Massachusetts Male Aging Study. Am J Epidemiol 2001; 153: 79-89
15. Ohlsson C, Labrie F, Barrett-Connor E et al. Low serum levels of dehydroepiandrosterone sulfate predict all-cause and cardiovascular mortality in elderly Swedish men. J Clin Endocrinol Metab 2010; 95: 4406-4414
16. Webb SJ, Geoghegan TE, Prough RA et al. The biological actions of dehydroepiandrosterone involves multiple receptors. Drug Metab Rev 2006; 38: 89-116
17. Widstrom RL, Dillon JS. Is there a receptor for dehydroepiandrosterone or dehydroepiandrosterone sulfate? Semin Reprod Med 2004; 22: 289-298
18. Szucs J, Bodrogi L. Androsterone sulphate, dehydroepiandrosterone sulphate and free dehydroepiandrosterone in uraemic patients. Horm Metab Res 1980; 12: 417-418
19. Winer RL, Rajudin MM, Skowsky WR et al. Preservation of normal adrenal androgen secretion in end stage renal disease. Metabolism 1982; 31: 269-273
20. Rainey WE, Carr BR, Sasano H et al. Dissecting human adrenal androgen production. Trends Endocrinol Metab 2002; 13: 234-239
21. Marx C, Petros S, Bornstein SR et al. Adrenocortical hormones in survivors and nonsurvivors of severe sepsis: diverse time course of dehydroepiandrosterone, dehydroepiandrosterone-sulfate, and cortisol. Crit Care Med 2003; 31: 1382-1388
22. Akishita M, Hashimoto M, Ohike Y et al. Association of plasma dehydroepiandrosterone-sulfate levels with endothelial function in postmenopausal women with coronary risk factors. Hypertens Res 2008; 31: 69-74
23. Kawano H, Yasue H, Kitagawa A et al. Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. J Clin Endocrinol Metab 2003; 88: 3190-3195
24. Rice SP, Agarwal N, Bolusani H et al. Effects of dehydroepiandrosterone replacement on vascular function in primary and secondary adrenal insufficiency: a randomized crossover trial. J Clin Endocrinol Metab 2009; 94: 1966-1972
25. Arlt W, Hewison M. Hormones and immune function: implications of aging. Aging Cell 2004; 3: 209-216
26. Altman R, Motton DD, Kota RS et al. Inhibition of vascular inflammation by dehydroepiandrosterone sulfate in human aortic endothelial cells: roles of PPARalpha and NF-kappaB. Vascul Pharmacol 2008; 48: 76-84
27. Urata Y, Goto S, Kawakatsu M et al. DHEA attenuates PDGFinduced phenotypic proliferation of vascular smooth muscle A7r5 cells through redox regulation. Biochem Biophys Res Commun 2010; 396: 489-494
28. Carrero JJ, Kyriazis J, Sonmez A et al. Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD. Clin J Am Soc Nephrol 2012; 7: 207-215
29. Straub RH, Zeuner M, Lock G et al. High prolactin and low dehydroepiandrosterone sulphate serum levels in patients with severe systemic sclerosis. Br J Rheumatol 1997; 36: 426-432
30. Brzoza Z, Kasperska-Zajac A, Rogala B. Serum prolactin concentration and its relationship with dehydroepiandrosterone sulfate concentration in chronic urticaria patients with positive and negative response to autologous serum skin test. Allergy 2007; 62: 566-567
31. Higuchi K, Nawata H, Maki T et al. Prolactin has a direct effect on adrenal androgen secretion. J Clin Endocrinol Metab 1984; 59: 714-718
32. Glasow A, Breidert M, Haidan A et al. Functional aspects of the effect of prolactin (PRL) on adrenal steroidogenesis and distribution of the PRL receptor in the human adrenal gland. J Clin Endocrinol Metab 1996; 81: 3103-3111
33. Carrero JJ, Qureshi AR, Parini P et al. Low serum testosterone increases mortality risk among male dialysis patients. J Am Soc Nephrol 2009; 20: 613-620
34. Carrero JJ, Qureshi AR, Nakashima A et al. Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. Nephrol Dial Transplant 2011; 26: 184-190
35. Barrett-Connor E, Goodman-Gruen D. Dehydroepiandrosterone sulfate does not predict cardiovascular death in postmenopausal women. The Rancho Bernardo Study. Circulation 1995; 91: 1757-1760
36. Baulieu EE, Thomas G, Legrain S et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci USA 2000; 97: 4279-4284
37. Shufelt C, Bretsky P, Almeida CM et al. DHEA-S levels and cardiovascular disease mortality in postmenopausal women: results from the National Institutes of Health-National Heart, Lung, and Blood Institute (NHLBI)-sponsored Women's Ischemia Syndrome Evaluation (WISE). J Clin Endocrinol Metab 2010; 95: 4985-4992
38. Fukai S, Akishita M, Yamada S et al. Plasma sex hormone levels and mortality in disabled older men and women. Geriatr Gerontol Int 2011; 11: 196-203
39. Rosenfeld RS, Rosenberg BJ, Fukushima DK et al. 24-hour secretory pattern of dehydroisoandrosterone and dehydroisoandrosterone sulfate. J Clin Endocrinol Metab 1975; 40: 850-855
40. Goodkin DA, Bragg-Gresham JL, Koenig KG et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2003; 14: 3270-3277.